Start date: 30/07/2020 09:30

End date: 30/07/2020 10:30

Venue: Webinar

Costs: Free of Charge

Open for: CBBC Members only

Address: Online

Click to register

Opportunities and Regulatory Implications Associated with the Rise of China’s Digital Economy in Healthcare - a CBBC Digital China Webinar with Cisema

CBBC Event

July 30
This webinar is part of our member-only Digital China programme. Composed of a series of briefings, panel discussions and webinars, it is designed to provide an overview of Chinese government policy, followed by a deep dive into activities in key sectors. 

Join us as we welcome Anna King and Hamish King, long-standing regulatory affairs experts from Cisema to present on the market opportunities and regulatory implications of the fast-growing digital healthcare sector in China. Covid-19 has only served to further accelerate favourable market tailwinds. Telehealth, AI and other key digital health trends in China will be discussed, and the regulatory framework analysed.
In this interactive webinar session, we will explore:
 
  • What are the key digital health trends in China?
  • How does risk class classification for the NMPA (former CFDA) work?
  • Are there any fast-track regulatory pathways?
  • What are the latest updates regarding digital health regulations?

Cisema’s experts will answer your questions and better equip you to access China’s digital health market.

Speakers Biography

 
Anna King
Partner and Business Consultant, Cisema


Anna King attained degrees with distinction in Natural Sciences (BSc) and China Business (MSc) in England and Hong Kong and has been working for Cisema group since 2013. She has been advising companies on China certification as a business consultant of Cisema in Munich, Beijing and Hong Kong. Mrs. King currently resides in Hong Kong and has specialised in NMPA (former CFDA) registration of medical devices, cosmetics, and other life science products.

 
Hamish King
Director, Cisema


Hamish King is a lawyer admitted in New South Wales, Australia and formerly with Linklaters in Hong Kong. He supports companies with difficult regulatory affairs queries for China, and regularly writes articles on China market access and regulatory pathways. Currently residing in Hong Kong and specialising in NMPA registration of medical devices, he has a close interest in the regulatory implications of digital healthcare and AI applications.



Cisema is a turn-key regulatory affairs solutions provider for China and Hong Kong for medical device, IVD, pharmaceutical packaging & APIs and cosmetics manufacturers. Founded in 2002 in Munich, Germany and Beijing, China, Cisema have offices globally. Cisema is a one-stop service provider supporting UK and global companies register their products for sale in China (including clinical studies). Cisema also provides post-market surveillance support and can act as legal agent so you don't have to set up an office in China.